drugset / Trial / NCT07454382
A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether the combination of elranatamab and cyclophosphamide is an effective treatment for people with relapsed/refractory multiple myeloma (MM) who have risk factors that may affect how well their disease would respond to elranatamab alone.
Timeline
- Start
- 2026-02-27
- Primary completion
- 2029-08-27
- Completion
- 2029-08-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Elranatamab | Monoclonal antibody | — | — |